Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 2Brain Neoplasms 2Oligodendroglioma 1Gliosarcoma 1Glioma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 128Radiotherapy 85Bevacizumab 43Radiation 30Carmustine 29Irinotecan 22Erlotinib Hydrochloride 22Magnetic Resonance Spectroscopy 21Chemotherapy, Adjuvant 20Surgical Procedures, Operative 15O(6)-benzylguanine 15Carboplatin 14Radiotherapy, Intensity-Modulated 13Radiotherapy, Conformal 13sargramostim 12Sirolimus 9Imatinib Mesylate 9Filgrastim 9temsirolimus 8Thalidomide 8Sorafenib 8Radiosurgery 8Drug Therapy 8pembrolizumab 7motexafin gadolinium 7aldesleukin 7Vorinostat 7Procarbazine 7Gene Expression Profiling 7Gefitinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gliosarcoma × trebananib × CNS × Clear all
NCT01609790 2022-07-21

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

National Cancer Institute (NCI)

Phase 2 Completed
137 enrolled 13 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡